leadf
logo-loader
viewGeron

Geron reveals positive findings on cancer treatment imetelstat

Biopharma group Geron unveiled positive findings from studies of its innovative cancer treatment imetelstat

CancerHeadline_57177f89707df.jpg
The first poster presentation revealed that treating acute myeloid leukemia (AML) cells with imetelstat enhanced the effects of agents currently used for treating the disease...

Biopharma group Geron Corporation (NASDAQ:GERN) unveiled positive findings from studies of its innovative cancer treatment imetelstat at a New Orleans conference.

The first poster presentation revealed that treating acute myeloid leukemia (AML) cells with imetelstat enhanced the effects of agents currently used for treating the disease.

The second showed results from non-clinical studies, which backed up findings of previous clinical trials, concerning blood platelet production.

The work was presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting held in New Orleans, Louisiana.

Imetelstat inhibits the activity of telomerase - an enzyme present in most types of cancer that enables tumor cells to replicate indefinitely.

Imetelstat has not, as yet, been approved for marketing by any regulatory authority.

The firm  is developing the treatment under a collaboration agreement with Janssen Biotech, Inc.

In late 2014, Geron entered an exclusive worldwide license and collaboration agreement with Janssen to develop and commercialize imetelstat for oncology, including hematologic myeloid malignancies, and all other human therapeutics uses.

Under the terms, Geron received an upfront payment of $35 million and is eligible to receive additional payments up to a potential total of $900 million for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales.

Certain regulatory, development, manufacturing and promotional activities are being managed through a joint governance structure, with Janssen responsible for these activities.

Janssen is conducting two imetelstat clinical trials: a Phase 2 clinical trial in patients with intermediate-2 and high risk myelofibrosis (MF) and a Phase 2/3 clinical trial in patients with low and intermediate-1 risk myelodysplastic syndromes (MDS).

Quick facts: Geron

Price: 1.85 USD

NASDAQ:GERN
Market: NASDAQ
Market Cap: $574.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Altamira Gold Corp releases positive channel results as the project moves...

Altamira Gold (CVE: ALTA-OTC: EQTRF) CEO Michael Bennett joined Steve Darling from Proactive to share details about the recent work at their at the Cajueiro gold project in Brazil. That trenching work has identified several new mineralized structures. Bennett shared details about that work...

7 hours, 35 minutes ago

2 min read